Opinicus Capital Inc. purchased a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 819 shares of the pharmaceutical company's stock, valued at approximately $397,000.
Several other large investors have also modified their holdings of VRTX. ABC Arbitrage SA acquired a new stake in shares of Vertex Pharmaceuticals in the 4th quarter valued at approximately $1,510,000. Highview Capital Management LLC DE lifted its holdings in Vertex Pharmaceuticals by 1.8% in the fourth quarter. Highview Capital Management LLC DE now owns 5,771 shares of the pharmaceutical company's stock valued at $2,324,000 after acquiring an additional 102 shares during the period. Davidson Investment Advisors boosted its position in shares of Vertex Pharmaceuticals by 26.0% during the 4th quarter. Davidson Investment Advisors now owns 61,161 shares of the pharmaceutical company's stock worth $24,630,000 after purchasing an additional 12,631 shares in the last quarter. Jones Financial Companies Lllp boosted its position in shares of Vertex Pharmaceuticals by 75.5% during the 4th quarter. Jones Financial Companies Lllp now owns 2,468 shares of the pharmaceutical company's stock worth $994,000 after purchasing an additional 1,062 shares in the last quarter. Finally, New York State Common Retirement Fund increased its holdings in shares of Vertex Pharmaceuticals by 0.8% in the 4th quarter. New York State Common Retirement Fund now owns 362,334 shares of the pharmaceutical company's stock valued at $145,912,000 after purchasing an additional 2,855 shares in the last quarter. Hedge funds and other institutional investors own 90.96% of the company's stock.
Vertex Pharmaceuticals Stock Down 1.0%
Shares of NASDAQ VRTX traded down $4.54 on Monday, hitting $450.91. The company had a trading volume of 1,029,911 shares, compared to its average volume of 1,602,498. The company has a quick ratio of 2.35, a current ratio of 2.69 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a 12-month low of $377.85 and a 12-month high of $519.88. The firm has a market capitalization of $115.79 billion, a P/E ratio of -204.96, a PEG ratio of 2.11 and a beta of 0.41. The business has a 50 day moving average of $462.54 and a two-hundred day moving average of $460.10.
Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.29 by ($0.23). The firm had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.85 billion. Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. The firm's revenue was up 2.6% compared to the same quarter last year. During the same period last year, the business earned $4.76 EPS. As a group, equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of analysts recently commented on VRTX shares. Leerink Partnrs downgraded shares of Vertex Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 6th. Wolfe Research lowered Vertex Pharmaceuticals from an "outperform" rating to a "peer perform" rating in a research note on Wednesday, May 7th. Morgan Stanley upped their price target on Vertex Pharmaceuticals from $462.00 to $464.00 and gave the stock an "equal weight" rating in a report on Tuesday, May 6th. Scotiabank lowered their price target on shares of Vertex Pharmaceuticals from $450.00 to $442.00 and set a "sector perform" rating on the stock in a research report on Tuesday, May 6th. Finally, Royal Bank of Canada raised their price objective on shares of Vertex Pharmaceuticals from $420.00 to $423.00 and gave the stock a "sector perform" rating in a research note on Tuesday, May 6th. Fourteen investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $515.04.
View Our Latest Report on VRTX
Vertex Pharmaceuticals Company Profile
(
Free Report)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Recommended Stories

Before you consider Vertex Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.
While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.